You are here

ENMD-2076

EntreMed commences ENMD-2076 Phase 2 trial

EntreMed commences ENMD-2076 Phase 2 trial

The Fly on the Wall

Flag link:

EntreMed announces initiation of phase 2 trial in triple-negative breast cancer

EntreMed announces initiation of phase 2 trial in triple-negative breast cancer

Yahoo/Fly on the Wall

triple-negative breast cancer

Flag link:

EntreMed shares spike on PhII cancer data

EntreMed shares spike on PhII cancer data

Fierce Biotech

Flag link:

EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients

EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients

Yahoo/PR NewsWire

Flag link:

Six Trades on FDA, Clinical Trial Binary Events

Six Trades on FDA, Clinical Trial Binary Events

Seeking Alpha

Protalix BioTherapeutics

cancer vaccines

Flag link:

EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer

EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer

Yahoo/PR NewsWire

Aurora A/angiogenic kinase inhibitor

Flag link: